 SHELTON, CT ACCESSWIRE July 8, 2020 NanoViricides, Inc. NYSE American:NNVC the Company a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform the Company, today announced the commencement of an underwritten public offering. The Company intends to use the net proceeds from this offering to fund general corporate purposes including its drug development programs for COVID-19 and for shingles. The Company has also granted the underwriters a 45-day option to purchase 15 additional shares of common stock to cover over-allotments at the public offering price. 